12:00 AM
Nov 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

A3309: Phase IIb started

Albireo began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 3 doses of oral A3309 given once daily in 180 patients with...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >